RJS, what I truly cannot understand, is Generex aside, no one unless it is hush, hush is taking a look at NGIO. With the past track record of breast cancer research, 10 year study paper, everything, literally there is zip on it and yet it is still filed for NASDAQ.

NGIO is a make or break company and yet, there is utter silence out there which makes no sense.

I won't even discuss the wound care that was supposed to take off...